Skip to main content
Premium Trial:

Request an Annual Quote

Gerald Möller

Ayoxxa Biosystems said that Gerald Möller has joined its board as an independent director and as its chairman. He will guide the firm's expansion from life science research into disease-specific applications for Ayoxxa's Lunaris multiplexing technology. Möller has 40 years of management experience in the diagnostic and pharmaceutical industries and was most recently an investment advisor to HMB Partners. He held senior management positions at Boehringer Mannheim from 1975 to 1998 and became CEO of the worldwide operating group in 1995. He was also a board member at Illumina before leaving in May. He currently is chairman of Morphosys.  

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.